ロード中...
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol
BACKGROUND: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation of drug efficacy: a multi-arm multi-stage platform randomised controlled pr...
保存先:
| 出版年: | Ann Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5961425/ https://ncbi.nlm.nih.gov/pubmed/29529169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy072 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|